NASDAQ:CYTK

Cytokinetics Competitors

$24.70
-0.17 (-0.68 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.68
Now: $24.70
$24.78
50-Day Range
$18.57
MA: $22.61
$25.68
52-Week Range
$13.45
Now: $24.70
$30.14
Volume573,796 shs
Average Volume920,504 shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45

Competitors

Cytokinetics (NASDAQ:CYTK) Vs. ARWR, GWPH, ASND, TGTX, IONS, and SRPT

Should you be buying CYTK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cytokinetics, including Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), and Sarepta Therapeutics (SRPT).

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Arrowhead Pharmaceuticals and Cytokinetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Cytokinetics-209.88%-3,065.14%-36.39%

Valuation & Earnings

This table compares Arrowhead Pharmaceuticals and Cytokinetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million79.80$-84,550,000.00($0.84)-80.54
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71

Arrowhead Pharmaceuticals has higher revenue and earnings than Cytokinetics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Arrowhead Pharmaceuticals and Cytokinetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals021002.83
Cytokinetics011002.91

Arrowhead Pharmaceuticals currently has a consensus target price of $85.3077, suggesting a potential upside of 26.10%. Cytokinetics has a consensus target price of $33.6364, suggesting a potential upside of 36.18%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats Cytokinetics on 8 of the 13 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 6.4% of Cytokinetics shares are held by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cytokinetics and GW Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
GW Pharmaceuticals010402.29

Cytokinetics presently has a consensus target price of $33.6364, suggesting a potential upside of 36.18%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.77%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytokinetics is more favorable than GW Pharmaceuticals.

Risk & Volatility

Cytokinetics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Profitability

This table compares Cytokinetics and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Earnings & Valuation

This table compares Cytokinetics and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08

GW Pharmaceuticals has higher revenue and earnings than Cytokinetics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Cytokinetics (NASDAQ:CYTK) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are held by institutional investors. 6.4% of Cytokinetics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cytokinetics and Ascendis Pharma A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
Ascendis Pharma A/S011102.92

Cytokinetics presently has a consensus target price of $33.6364, suggesting a potential upside of 36.18%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 53.89%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Cytokinetics.

Risk & Volatility

Cytokinetics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Profitability

This table compares Cytokinetics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Earnings & Valuation

This table compares Cytokinetics and Ascendis Pharma A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
Ascendis Pharma A/S$14.98 million437.57$-244,180,000.00($5.25)-23.23

Cytokinetics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Summary

Cytokinetics beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cytokinetics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
TG Therapeutics-151,798.69%-223.96%-108.08%

Valuation & Earnings

This table compares Cytokinetics and TG Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
TG Therapeutics$150,000.0041,969.61$-172,870,000.00($1.83)-24.47

Cytokinetics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cytokinetics and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
TG Therapeutics00503.00

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.92%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Cytokinetics.

Cytokinetics (NASDAQ:CYTK) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cytokinetics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
Ionis Pharmaceuticals7.82%6.57%3.39%

Valuation & Earnings

This table compares Cytokinetics and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
Ionis Pharmaceuticals$1.12 billion5.12$303.26 million$2.0819.61

Ionis Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cytokinetics and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
Ionis Pharmaceuticals27602.27

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 42.00%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Cytokinetics.

Summary

Ionis Pharmaceuticals beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cytokinetics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Valuation & Earnings

This table compares Cytokinetics and Sarepta Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
Sarepta Therapeutics$380.83 million14.97$-715,080,000.00($9.71)-7.39

Cytokinetics has higher earnings, but lower revenue than Sarepta Therapeutics. Cytokinetics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cytokinetics and Sarepta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
Sarepta Therapeutics191302.52

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Sarepta Therapeutics has a consensus price target of $150.4762, suggesting a potential upside of 109.58%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Cytokinetics.

Summary

Sarepta Therapeutics beats Cytokinetics on 8 of the 14 factors compared between the two stocks.


Cytokinetics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65-0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90-0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95-1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78-2.3%$6.30 billion$150,000.00-21.12Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80-1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50-3.5%$5.55 billionN/A-38.14Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20-0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90-0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15-0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40-1.9%$4.62 billionN/A-6.06Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64-1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59-0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07-1.7%$3.42 billion$136.47 million-12.72News Coverage
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15-0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
MorphoSys logo
MOR
MorphoSys
0.3$22.65-2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46-5.3%$2.75 billion$260.98 million-357.67Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39-0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26-5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73-0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13-5.6%$2.35 billion$15 million-17.35Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.